Compare
Immuneering Corp vs Design Therapeutics, Inc. vs Evolus, Inc. vs Pliant Therapeutics, Inc.
| Latest fiscal year | Immuneering Corp IMRX | Design Therapeutics, Inc. DSGN | Evolus, Inc. EOLS | Pliant Therapeutics, Inc. PLRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $0 | $297.18M | $0 |
| Revenue growth (YoY) | n/a | n/a | +11.6% | n/a |
| Gross margin | n/a | n/a | 66.3% | n/a |
| Operating margin | n/a | n/a | -11.0% | n/a |
| Net margin | n/a | n/a | -17.4% | n/a |
| Net income | -$56.02M | -$69.79M | -$51.64M | -$149.34M |
| EPS (Diluted) | -$1.27 | -$1.22 | -$0.80 | -$2.43 |
| Operating cash flow | -$45.34M | -$54.36M | -$42.27M | -$128.34M |
| Free cash flow | -$45.49M | -$54.55M | -$45.71M | -$128.71M |
| Cash & equivalents | $128.65M | $16.86M | $53.83M | $45.45M |
| Total assets | $231.99M | $226.20M | $225.87M | $225.23M |
| Total liabilities | $13.50M | $13.70M | $248.97M | $44.02M |
| Shareholders' equity | $218.48M | $212.50M | -$23.11M | $181.21M |
| Return on year-end equity | -25.6% | -32.8% | n/a | -82.4% |
| Shares outstanding | n/a | 60.40M | 65.01M | 61.45M |
Revenue, most recent five fiscal years
| Fiscal year | Immuneering Corp | Design Therapeutics, Inc. | Evolus, Inc. | Pliant Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2023-12-31 | $0 Ended 2025-12-31 | $297.18M Ended 2025-12-31 | $0 Ended 2025-12-31 |
| 1 year earlier | $317.0K Ended 2022-12-31 | $0 Ended 2024-12-31 | $266.27M Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | $2.08M Ended 2021-12-31 | n/a | $202.09M Ended 2023-12-31 | $1.58M Ended 2023-12-31 |
| 3 years earlier | $2.31M Ended 2020-12-31 | n/a | $148.62M Ended 2022-12-31 | $9.69M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $99.67M Ended 2021-12-31 | $7.57M Ended 2021-12-31 |